You are here

Article Text

Article menu
Download PDFPDF
Motility and visceral sensation
Effects of a serotonin 5-HT4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans
  1. A E Bharuchaa,
  2. M Camilleria,
  3. S Haydockc,
  4. I Ferbera,
  5. D Burtona,
  6. S Cooperc,
  7. D Tompsonc,
  8. K Fitzpatrickc,
  9. R Higginsc,
  10. A R Zinsmeisterb
  1. aGastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA, bSection of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA, cSmithKline Beecham Pharmaceuticals, Harlow, UK
  1. Dr A E Bharucha, Mayo Clinic, Enteric Neuroscience Group, GI Research Unit-Alfred 2-435, 200 First St SW, Rochester, MN 55905, USA.bharucha.adil{at}mayo.edu

Abstract

BACKGROUND Serotonin 5-HT4 receptors are located on enteric cholinergic neurones and may regulate peristalsis. 5-HT4 receptors on primary afferent neurones have been postulated to modulate visceral sensation. While 5-HT4 agonists are used as prokinetic agents, the physiological role of 5-HT4 receptors in the human gut is unknown.

AIMS Our aim was to characterise the role of 5-HT4 receptors in regulating gastrointestinal motor and sensory function in healthy subjects under baseline and stimulated conditions with a 5-HT4 receptor antagonist.

METHODS Part A compared the effects of placebo to four doses of a 5-HT4receptor antagonist (SB-207266) on the cisapride mediated increase in plasma aldosterone (a 5-HT4 mediated response) and orocaecal transit in 18 subjects. In part B, 52 healthy subjects received placebo, or 0.05, 0.5, or 5 mg of SB-207266 for 10–12 days; gastric, small bowel, and colonic transit were measured by scintigraphy on days 7–9, and fasting and postprandial colonic motor function, compliance, and sensation during distensions were assessed on day 12.

RESULTS Part A: 0.5, 5, and 20 mg doses of SB-207266 had significant and quantitatively similar effects, antagonising the cisapride mediated increase in plasma aldosterone and acceleration of orocaecal transit. Part B: SB-207266 tended to delay colonic transit (geometric centre of isotope at 24 (p=0.06) and 48 hours (p=0.08)), but did not have dose related effects on transit, fasting or postprandial colonic motor activity, compliance, or sensation.

CONCLUSION 5-HT4receptors are involved in the regulation of cisapride stimulated orocaecal transit; SB 207266 tends to modulate colonic transit but not sensory functions or compliance in healthy human subjects.

  • 5-HT4 receptors
  • colon transit
  • gastrointestinal motor function
  • gastrointestinal sensory function

  • Abbreviations used in this paper

    AUC
    area under the plasma concentration curve
    Cmax
    maximal concentration
    GC
    geometric centre
    MI
    motility index

    • https://doi.org/10.1136/gut.47.5.667

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    • Abbreviations used in this paper

      AUC
      area under the plasma concentration curve
      Cmax
      maximal concentration
      GC
      geometric centre
      MI
      motility index
      • View Full Text